Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Daiichi Sankyo
Pharma
Novartis, Neurocrine-Takeda, Enhertu—Fierce Pharma Asia
Novartis is mitigating a potential threat from the BIOSECURE Act. A Neurocrine drug from Takeda posted a trial win. Enhertu nears a HER2-low readout.
Angus Liu
Apr 26, 2024 5:45am
Geopolitical tensions, Carvykti, Enhertu—Fierce Pharma Asia
Apr 12, 2024 8:20am
AZ, Daiichi's Enhertu cleared by FDA in wide range of tumors
Apr 8, 2024 10:49am
Abzena earmarks $5M to bolster ADC services at Pennsylvania site
Mar 28, 2024 8:40am
Daiichi Sankyo, Astellas, Novartis and more—Fierce Pharma Asia
Feb 23, 2024 8:06am
Novo Nordisk, Eli Lilly lead industrywide sales surge in Q4
Feb 22, 2024 3:20pm